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Midkine (MK) is a heparin-binding growth factor and was found to be highly expressed in many types of 
human carcinomas. MK may become a novel tumor marker. In this study, we used the rabbit specific 
antibodies against human MK to establish a double antibody sandwich enzyme-linked immunosorbent 
assay (ELISA) of MK system and applied it to detect serum MK levels in different types of cancer 
patients. The standard curve, precision and recovery rate were tested, respectively, and serum MK 
concentration of 102 cancers patients and 102 normal individuals were detected using this method. The 
detection range of this method was 0.2 to 10 ng/ml (R
2 
= 0.97). The average intra and intro-assay 
coefficients of variation (CVs) were 3.6 and 7.9%, respectively. The average recovery rate was 89.9% 
when some standard antigens were added into the serum. The medians (25th and 75th percentiles) of 
serum MK levels were 1.35 ng/ml (0.96 and 1.64) in cancer patients and 0.30 ng/ml (0.23 and 0.38) in the 
controls; the MK levels of the patients were significantly higher than those of the controls (P<0.05). 
Moreover, 87.2% of the patients showed more than 0.6 ng/ml levels of MK. Serum MK could serve as a 
general tumor marker with a good potential for clinical application. 
 





Midkine (MK) is a heparin-binding growth factor found as 
the product of a retinoic acid-responsive gene 
(Kadomatsu et al., 1988). It has 45% sequence identity to 
pleiotrophin [(PTN)/heparin-binding growth-associated 
molecule (HB-GAM)], and together, these molecules 
comprise a family of heparin-binding growth factors 
(Tomomura et al., 1990). MK has been implicated in 
diverse activities, for example, it enhances angiogenic 
activities of tumour cells (Choudhui et al., 1997), it 
promotes cell survival and cell migration, and is deeply 
involved in cancer progression. It is highly expressed at 
both mRNA and protein levels in many human carci-
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colorectal,   liver,   ovary,  urinary  bladder   and   prostate 
carcinomas, glioblastomas, neuroblastomas and Wilms’ 
tumours (Muramatsu et al., 1996; O'Brien et al., 1996; 
Takada et al., 1997). Furthermore, MK is a secreted 
protein; serum MK levels are expected to increase when 
tumors tissues express abundant MK. So, it is probable 
that MK would be a marker for diagnostic tumors through 
the detection of the levels of MK in the patients’ serum. In 
this study, we employed sandwich ELISA to analyze 
serum samples from 102 cancer patients and 102 
controls. It was suggested that sandwich ELISA of MK 
would likely be applied to assist in the diagnosis of 
various tumors and that is has enormous clinical marker.  
 
 
MATERIALS AND METHODS 
 
MK monoclonal antibodies 
 
The rabbit anti-human midkine monoclonal antibodies were 
preserved in our laboratory. As described previously, prokaryotic 
expressed MK protein were immunize into rabbits to prepare 
monoclonal antibodies against human MK by the  rabbit  hybridoma 







Figure 1. Standard curve of sandwich ELISA using recombinant MK. MK protein was 




technique, then hybridoma cell line secreting anti-MK mAb was 






Sera were obtained from blood collected from the cancer patients 
and normal individuals. The patients with inflammatory condition 
such as diabetes mellitus, rheumatoid arthritis and hepatitis were 
excluded. Informed consent was obtained from patients and normal 
individuals.  
Cancer patients (n = 102; male = 79; female = 23; ages 31 to 85; 
average value = 58.6) and normal individuals (n = 102; male = 79; 
female = 23; ages 20 to 81; average value = 50.3) were used. 3 ml 
of sera were immediately frozen and kept at -80°C until the assay. 
 
 
Construction and application of ELISA for detection of serum 
MK levels 
 
Each well of a 96-well microplate was coated with 100 µl of goat 
anti-human MK poly antibody (R&D, Minneapolis, USA) diluted to 
1.25, 2.5, 5, 7.5 and 10 µg/ml, respectively, then was incubated for 
30 min at 37°C followed by overnight incubation at 4°C. After 
washing wells with PBS containing 0.05% Tween 20 (PBST), 300 µl 
of 1% bovine serum albumin in PBST was added to each well to 
block non-specific binding sites. After 1 h incubation at room 
temperature, wells were washed three times with PBST, 100 µl of 5 
ng/ml purify MK protein was added and incubated for 1 h at room 
temperature. Then, wells were washed three times with PBST; 
incubated with 100 µl of rabbit anti-human mAb of MK for 1 h at 
room temperature. The wells were again washed, and the HRP 
conjugated IgG (1:1000) was added for 1 h at room temperature, 
and finally, incubated with a substrate solution (100 µl TMB) for 10 
min. The reaction was stopped by adding 100 µl of 2 N sulphuric 
acid, and OD450 was detected using a multiplate reader.  
Accurate sample concentrations of human MK were determined 
by comparing specific absorbances with those obtained from the 
standards plotted on a standard curve. Serum from a healthy donor 
was used as a negative control. The ELISA was subsequently used 






Data were analyzed with SPSS software 12.0. As the serum MK 
levels of patients were non normal distribution, the data were 
presented as median with percentile values. Difference between the 
two groups was evaluated by non-parametric Mann-Whitney U test. 
Correlation was examined by Spearman’s correlation coefficient. 
Differences were considered to be statistical significant when the P 
value was less than 0.05. 
 
 
RESULTS AND DISCUSSION 
 
Establishment of sandwich ELISA of MK 
 
A sandwich ELISA was developed using the anti-human 
MK ploy and monoclonal antibody. The standard curve 
using purified recombinant MK is shown in Figure 1, with 
sandwich ELISA. In this ELISA, dose-dependent increase 
in the absorbance at 450 nm enables the measuring of 
MK ranging between 0.2 and 10 ng/ml. The intra- and 
inter-assay variabilities of the ELISA curve for MK were 
used to show the precision of this method. The intra-
assay variability was given by the average of nine 
replicated wells in 1 microplate. The interassay variability 
was given by the average of eight replicated microplates 
at various times. The intra- and inter-assay coefficients of 
variation (CVs) were 4.16, 3.12, 3.52 and 4.25, 9.77 and 
8.29%, respectively (Table 1), which showed that it was 
feasible to apply this method to detect MK in various 
tumor serum. The accuracy of MK sandwich ELISA was 
evaluated with recovery rate analysis. The average 
recovery rate  of  MK   in   the  serum   was   89.9%.   The  




Table 1. Coefficients of variation of MK level by sandwich ELISA assay. 
 
Sample ID 
Intra-assay (n = 8) 
CV (%) 
Inter-assay (n = 5) 
CV (%) Mean ±SD (ng/ml) Mean ±SD (ng/ml) 
1 1.68±0.07 4.16 0.94±0.04 4.25 
2 1.28±0.04 3.12 1.33±0.13 9.77 
3 4.54±0.16 3.52 4.34±0.36 8.29 
 




Table 2. Precision of MK from serum by sandwich ELISA assay. 
 
Midkine (ng/ml) Measure (ng/ml) Recovery rate (%) 
1.01 0.92 91.1 
1.76 1.53 86.9 
2.51 2.13 84.9 
2.87 2.94 92.4 
3.62 3.29 90.9 




Table 3. Application of sandwich ELISA for the detection of MK in various tumors serum. 
 
Tumor Number Male/female 
Year 
(mean) 
MK (ng/ml) (25th and 75th 
percentiles medians) 
P 
Lung carcinoma 13 12/1 63.1 0.93 (0.52 and 1.56) < 0.05 
Gastric carcinoma 40 10/30 58.5 1.43 (1.19 and 1.77) < 0.05 
Esophageal carcinoma 12 12/0 63.5 1.23 (0.97 and 1.46) < 0.05 
Colon carcinoma 19 12/7 58.5 1.26 (0.96 and 1.47) < 0.05 
Hepatocellular carcinoma 11 9/2 49.2 1.23 (0.56 and 1.38) < 0.05 
Pancreatic carcinoma 7 4/3 55.4 1.48 (0.92 and 2.64) < 0.05 
Patients 102 79/23 58.6 1.35 (0.96 and 1.64) < 0.05 




samples’ recovery rates are given in Table 2. 
 
 
Application of ELISA to detect serum MK levels in 
cancer patients 
 
The median (25th and 75th percentiles) of serum MK 
levels of the 102 control individuals was 0.30 ng/ml (0.23 
and 0.38), and no case had the value above 0.6 ng/ml. 
The median (25th and 75th percentiles) of serum MK 
levels of 102 cancer patients was 1.35 ng/ml (0.96 and 
1.64). The serum MK levels of the cancer patients were 
higher than those of the controls (P < 0.05). Furthermore, 
the serum MK levels of 102 cancer patients in the six 
types of tumors showed a profile that was significantly 
different from those of the normal controls (P < 0.05) 
(Table 3). 87.2%of the cancer patients had a serum MK 
value higher than 0.6 ng/ml. Recently, it is was demon-
strated that MK expressed in carcinomatous tissues and 
secreted into the bloodstream, leads to an increase in 
serum MK level in cancer patients, and did not show 
specification for a particular tissue. So, it is suggested 
that MK would likely be a novel marker for diagnosing 
tumors.  
The ELISA for MK reported previously (Muramatsu et 
al.,1996) employed just polyconal anti-MK antibodies to 
detect MK level. In this study, we raised rabbit 
monoclonal antibodies against human MK to develop a 
sandwich immunoassay for the detection of levels of MK 
in the serum. More importantly, the ELISA was 
advantageous in that it uses an ordinary colorimetric 
detection system that is more convenient for clinical use. 
Indeed, a combination of two anti-human MK antibodies 
exhibited a much higher sensitivity in the detection of 
human MK than rabbit antibodies alone. Using this 
procedure, we analyzed sera from a large number of 
patients and found that serum MK levels were elevated in 
most of the cancer patients examined. The ratio of 
patients with increased serum MK levels to a total of 
cancer patients examined agreed with that of patients with 




increased MK expression in tumor tissues reported 
previously (Kato et al., 2000a, b; Koide et al., 1999; 
Obata et al., 2005; Ren et al., 2006; Shimada et al., 
2003). When the cutoff value was 0.6 ng/ml, the 
sensitivity and specificity of this assay was comparable to 
or higher than those of previous methods for the 
detection of serum MK (Ikematsu et al, 2000; Shimada et 
al., 2003a,b). 
Future studies are required to show whether the 
determination of serum MK through sandwich ELISA can 
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